Latham & Watkins Advises on VectivBio’s US$125 Million Underwritten Offering of Ordinary Shares

VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of US$7.50 per share. Investors who have agreed to purchase shares in the offering include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion's Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners, and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting discounts and commissions and offering expenses, VectivBio expects to receive total gross proceeds of approximately US$125 million. The offering is expected to close on or about October 17, 2022, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Kaj Nielsen and Isabelle Sawhney.